---
schema_version: "secwatch.filing_event.v1"
accession: "0001437749-24-038436"
form_type: "8-K"
ticker: "VXRT"
cik: "0000072444"
company_name: "Vaxart, Inc."
filed_at: "2024-12-27T23:59:59+00:00"
generated_at: "2026-05-28T23:10:01.154211+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Vaxart secures $37.7M additional BARDA funding for oral COVID-19 vaccine trial

## Summary
- Modification No. 4 increases allotted trial funding from ~$96.5M to ~$134.2M.
- Additional $37.7M for mRNA comparator acquisition and clinical site readiness.
- Total estimated ceiling raised by ~$4.6M to ~$460.7M.
- Trial compares Vaxart's oral XBB COVID-19 vaccine to an FDA-approved mRNA vaccine.

## SEC filing metadata
- accession: 0001437749-24-038436
- form_type: 8-K
- ticker: VXRT
- cik: 0000072444
- company_name: Vaxart, Inc.
- filed_at: 2024-12-27T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/72444/000143774924038436/0001437749-24-038436-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/72444/000143774924038436/vxrt20241227_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001437749-24-038436
- JSON: https://secwatch.observer/filing/0001437749-24-038436.json
- Plain text: https://secwatch.observer/filing/0001437749-24-038436.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.